"This results in a substantial decrease in the quality of life for the refractory angina patient," added Prof. Enio Buffolo.
Bone marrow is a natural source of a broad spectrum of cytokines involved in controlling angiogenic and inflammatory processes. Bone marrow white blood cells therefore play an important role in the angiogenic mechanism, contributing to the revascularization of the heart.
The researchers selected the intramyocardial route for injection based on prior experimental data showing higher myocardial stem cell uptake. Endpoints for patient improvement were based on the Canadian Cardiovascular Society Angina Classification (CCSAC) system. According to Dr. Hossne, the ReACT formulation, designed in compliance with Good Manufacturing Practices (GMP) standards criteria, was found to be safe and effective, supporting further study with a larger number of patients.
"Patient improvement by the subjective CCSAC measures was followed by a correlated reduction in the myocardium ischemic area," concluded Dr. Hossne. "This strongly suggests neoangiogenesis as the main mechanism of action for these cells."
Contact: Dr. Nelson Americo Hossne, Jr., Cardiovascular Surgery Division, Surgery Department, Paulista School of Medicine, Federal University of Sao Paulo, Botucato St.
740 Sao Paulo, Brazil ZIP 04023-900.
Tel: +55-11-8166-5050; fax: +55-11-5052-0386,
Apelin helps heart function after bone marrow transplant
Apelin, a newly described inotropic peptide (related to the force of heart muscle contracti
|Contact: David Eve|
Cell Transplantation Center of Excellence for Aging and Brain Repair